Hormonal
Pramlintide (120 mcg t.i.d. or 360 mcg b.i.d.) combined with lifestyle intervention produces greater initial weight loss and enhances long-term maintenance of that weight loss over 12 months compared to lifestyle intervention alone in obese subjects.
If you are obese and struggling to maintain weight loss, adding pramlintide (120 mcg three times daily or 360 mcg twice daily) to a structured lifestyle program (diet and exercise) can help you lose more weight initially and, crucially, keep it off for at least a year. The medication is taken as a small injection before meals. While nausea is a common side effect, it is usually mild, decreases over time, and does not prevent weight loss. This approach is for non-diabetic obese individuals without other major health exclusions.
When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss.
Why this rating
Randomized, double-blind, placebo-controlled trial with a 12-month duration, though with some attrition and self-selection bias in the extension.
Source
Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Steven R. Smith et al. · Diabetes Care · 2008
DOI 10.2337/dc08-0029
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →